Phase I Study of Tolerance and Pharmacokinetics of TQ-B3395 in Patients With Advanced Cancer
Latest Information Update: 05 Nov 2021
At a glance
- Drugs TQ B3395 (Primary)
- Indications Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Chia Tai Tianqing Pharmaceutical Group
- 14 Dec 2016 Status changed from not yet recruiting to recruiting.
- 08 Nov 2016 New trial record